#USA #Menlo Park, California #cystic fibrosis #BillionToOne #UNITY Screen

BillionToOne's UNITY Screen: Pioneering Cystic Fibrosis Prenatal Screening

In a groundbreaking development for expectant families, BillionToOne, Inc., a molecular diagnostics innovator, has unveiled the remarkable efficacy of its UNITY Fetal Risk™ Screen. This revolutionary test offers a unique approach to prenatal screening for cystic fibrosis (CF), allowing families more options for treatment. A recent publication in the peer-reviewed Journal of Cystic Fibrosis highlights the findings from the largest study conducted on prenatal cystic fibrosis screening to date.

Comprehensive Study Reveals Breakthrough Findings

The retrospective analysis included over 100,000 general-risk pregnant individuals, making it the most extensive validation of cell-free DNA (cfDNA) screening for CF. The results were striking: UNITY achieved 100% sensitivity in identifying high-risk pregnancies for cystic fibrosis, meaning it did not miss any cases. Impressively, 95% of those identified as high-risk carried CF mutations that are treatable with CFTR modulator therapy—drugs that address the underlying protein defect responsible for CF.

Among the participants, the study identified 2,587 carriers of cystic fibrosis comprising 296 diverse CFTR gene variants, extending beyond the widely recognized F508Del mutation. This comprehensive detection capability is significant for families as it shows the potential for a wider array of genetic variations to be identified early in pregnancies.

Timely Testing and Early Treatment Options

The UNITY Screen allows for testing as early as nine weeks of gestation, with a median turnaround time of just 8.7 weeks. This capacity permits families to confirm pregnancy risks quickly and potentially begin administering emerging in utero treatments, which have shown promise in improving neonatal outcomes for CF-affected infants. According to Dr. Aaron Trimble, an author of the study and pulmonologist, identifying CF-affected pregnancies early is a transformative advancement that could change life trajectories for babies diagnosed with cystic fibrosis.

Advantages Over Traditional Screening Methods

One of the most notable advantages of the UNITY test is that it does not require paternal DNA samples, which can often create logistical obstacles in genetic testing. Traditional carrier screening methods generally necessitate testing both parents, which can lead to incomplete assessments as many partners do not pursue their testing.

In contrast, the UNITY Fetal Risk™ Screen uses a single-sample approach, analyzing blood from the pregnant individual only. This shift not only streamlines the testing process but also provides a detailed quantitative fetal risk estimate, ranging between 1-in-5,000 to 9-in-10 risk, as opposed to the fixed maximum risk estimates of 1-in-4 presented by traditional screening techniques.

Technological Innovation behind UNITY

BillionToOne employs its proprietary Quantitative Counting Templates™ (QCT™) technology, which accurately quantifies fetal cfDNA variants. This innovative method paves the way for precise risk prediction for autosomal recessive conditions, like cystic fibrosis, thereby addressing a long-standing challenge in non-invasive prenatal testing.

Dr. Haywood Brown, Chief Medical Officer for Prenatal at BillionToOne, emphasized that this significant achievement in screening without the need for a partner sample directly tackles the prevalent issue where over half of partners fail to complete testing when the pregnant woman is identified as a carrier. By offering early insights, families can better prepare for their child's healthcare journey and explore advanced therapeutic options that could dramatically enhance life quality post-diagnosis.

Conclusion

As BillionToOne continues to push the boundaries of molecular diagnostics, the UNITY Fetal Risk™ Screen is set to revolutionize the landscape of prenatal screening for cystic fibrosis. With its unparalleled sensitivity and vast range of genetic variant detection, the importance of timely information becomes evident. Expecting families now have more reason to be hopeful, as innovative solutions open doors to better health outcomes for their unborn children. For further information, visit BillionToOne's website.